HT-SPR Technology Across Discovery Platforms | Therapeutic Antibody Screening | Novel Therapeutics

Presented by Noah T. Ditto, Technical Product Manager, Carterra In biotherapeutics candidate discovery and development, innovation during the COVID-19 pandemic has been led by a diverse set of strategies used to identify candidates. Within this highly competitive space traditional hybridoma and phage approaches now both contend with and are complemented by NGS and synthetic strategies to meet candidate timelines measured in weeks rather than years. Despite substantial market pressures driving more sophisticated and differentiated approaches, there are stages across these varied workflows where turnkey solutions can be implemented to eliminate bottlenecks. In this talk the role of HT-SPR and its successful enablement of COVID-19 therapeutics will be explored as a technology in biotherapeutics discovery that is deployable in any workflow. Using case studies this talk will highlight touchpoints common across otherwise distinct workflows where leveraging HT-SPR can highlight critical attributes for biotherapeutic candidate selection.